Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cytokine-induced beta-cell death is an important factor in the pathogenesis of
type 1 diabetes
mellitus (T1DM). The transcription factor NFkappaB plays an important role in cytokine-induced gene activation. Hence,
NFKB1
is a possible candidate gene for T1DM disposition. A polymorphic (CA) dinucleotide repeat microsatellite has been identified near the
NFKB1
gene. In a recent case-control study certain alleles of this
NFKB1
microsatellite marker showed strong association to T1DM. The aim of our study was to investigate whether the association between the
NFKB1
marker and T1DM could be confirmed in a Danish family collection. No T1DM association for any allele of the
NFKB1
microsatellite marker could however be demonstrated in Danish T1DM families. In conclusion, we could not confirm the highly significant T1DM association of certain alleles of the
NFKB1
marker previously reported.
...
PMID:Characterization of a nuclear-factor-kappa B (NFkappaB) genetic marker in type 1 diabetes (T1DM) families. 1242 26
Several functional genetic variants that can potentially modulate the activity of NFkappaB have been recently described. As reduced NFkappaB activity has been implicated in risk for autoimmune diabetes in the NOD mouse, these variants were tested for allelic association with
type 1 diabetes
(T1D) in a family based study. Alleles at markers in the TAB2/SUMO4 locus on chromosome 6q had been previously reported to be associated with T1D in two separate studies, but these studies disagreed on the identity of the risk allele. The current study failed to confirm either of these results. No significant evidence of association with T1D was obtained for three SNP markers in the TAB2/SUMO4 region. An additional functional variant in the promoter of the
NFKB1
gene that has been shown to directly affect the expression of NFkappaB was also tested.
...
PMID:Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type 1 diabetes. 1572 64
Beta cell loss occurs at the onset of
type 1 diabetes
and after islet graft. It results from the dysfunction and destruction of beta cells mainly achieved by apoptosis. One of the mediators believed to be involved in beta cell apoptosis is Fas, a transmembrane cell surface receptor transducing an apoptotic death signal and contributing to the pathogenesis of several autoimmune diseases. Fas expression is particularly induced in beta cells by inflammatory cytokines secreted by islet-infiltrating mononuclear cells and makes cells susceptible to apoptosis by interaction with Fas-ligand expressing cells. We have previously demonstrated that 1,25(OH)2D3, the active metabolite of vitamin D, known to exhibit immunomodulatory properties and prevent the development of
type 1 diabetes
in NOD mice, is efficient against apoptosis induced by cytokines in human pancreatic islets in vitro. The effects were mainly mediated by the inactivation of
NF-kappa-B
. In this study we demonstrated that 1,25(OH)2D3 was also able to counteract cytokine-induced Fas expression in human islets both at the mRNA and protein levels. These results were reinforced by our microarray analysis highlighting the beneficial effects of 1,25(OH)2D3 on death signals induced by Fas activation. Our results provides additional evidence that 1,25(OH)2D3 may be an interesting tool to help prevent the onset of
type 1 diabetes
and improve islet graft survival.
...
PMID:1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. 1650 54
Type 1 diabetes mellitus
(T1DM) is one of the long-time studied autoimmune disorders. The triggering of the autoimmune process has been ascribed to various genes active in the regulation of the cytokine gene transcription including the Rel/NF-kappaB gene family. In our study the gene polymorphism of HLA class II,
NFKB1
(
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
) and NFKBIA (inhibitor of nuclear factor kappa B) was tested. Patients were divided into the subgroups in relation to the disease type: T1DM in children, T1DM in adults, and Latent Autoimmune Diabetes in Adults (LADA). HLA-DRB1 (*)04 and HLA-DQB1 (*)0302 have been detected as risk factors for T1DM in adults and particularly in children (P<0.0001, OR=22.9 and 46.5 respectively). HLA-DRB1 (*)03 has been found as a single risk factor for LADA (P<0.0001, OR=4.9). We detected 15 alleles for the
NFKB1
gene polymorphism (CA-repeats) in the Czech population. The alleles were ranging in size from 114-142 bp corresponding to 10-25 CA repeats. Frequency of the A7 allele of
NFKB1
gene has been significantly increased in T1DM adults (P<0.01). There was no difference in A and a G allele frequency of NFKBIA gene between the control group and patients, but the association of the AA genotype of NFKBIA gene has been found for LADA (P<0.05). Summarizing our results we concluded that there is a high probability of association of gene polymorphism from Rel/NF-kappaB family with an autoimmune diabetes course. Due to the results obtained in the epidemiological study we have been looking also for the function significance of the genetic predisposition. No significant changes have been observed by real time PCR testing of HLA-DRB1 (*)04 gene and
NFKB1
gene expression between T1DM diabetic group with different HLA,
NFKB1
, NFKBIA genetic background.
...
PMID:HLA, NFKB1 and NFKBIA gene polymorphism profile in autoimmune diabetes mellitus patients. 1731 73